Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963899 | 0.94 | VNN1 (0.40) | VNN1NAMPTRIPK1CA12CA1 | |
| SCHEMBL9955963 | 0.94 | VNN1 (0.40) | VNN1NAMPTRIPK1CA12CA1 | |
| SCHEMBL4772640 | 0.84 | NAMPT (0.37) | VNN1NAMPTRIPK1CA12CA1 | |
| SCHEMBL26131508 | 0.82 | NAMPT (0.36) | VNN1NAMPTRIPK1SCD5POLB | |
| SCHEMBL26906148 | 0.82 | NAMPT (0.36) | VNN1NAMPTRIPK1SCD5POLB | |
| SCHEMBL16794429 | 0.81 | NAMPT (0.36) | VNN1NAMPTRIPK1FKBP1ASCD5 | |
| SCHEMBL20738584 | 0.81 | CHRM2 (0.41) | NAMPTSPR | |
| SCHEMBL17901822 | 0.79 | HPGD (0.44) | VNN1NAMPTSCD5SPR | |
| SCHEMBL18701781 | 0.78 | LMNA (0.50) | NAMPTRIPK1FKBP1ASPR | |
| SCHEMBL27132297 | 0.78 | EPHX2 (0.36) | NAMPTFKBP1APOLBL3MBTL1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| CN-109937038-A | Dicyclic nitrogen-containing heterocycle compound | 田边三菱制药株式会社 | 2019-06-25 | — | — | CN | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | VNN1 3386/4885NAMPT 289/4885RIPK1 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.